Back to search
FDAFDA · Food and drugs·Recall number D-1862-2019

Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.

Published September 25, 2019 · Recall initiated: September 6, 2019

Summary

FDA records drug Class II recall D-1862-2019, published September 25, 2019 and initiated September 6, 2019. Recalling firm: Torrent Pharma Inc.; Status: Terminated; Reported quantity: 2472 bottles; Lot: Lot #: BFE2E003, Exp 08/31/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if ANAGRELIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ANAGRELIDE
Manufacturer
Torrent Pharma Inc.
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot #: BFE2E003, Exp 08/31/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01. recalled?

Yes. FDA published recall D-1862-2019 on September 25, 2019. Reported hazard: Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ANAGRELIDE.